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1. Introduction
Alzheimer’s disease (AD) is a fatal neurodegenerative disorder characterized by a progressive
neuronal death and loss of cognitive functions. AD is the most common type of dementia and
its incidence rise to 10% in people aged over 90 [1]. Due to Increased longevity, it has been
estimated that the number of people suffering from this neurodegenerative disorder will rise
from 26.6 million cases in 2006 to 106,8 million worldwide in 2050 [2].
Although clinical intervention to halt the disease is inefficient, the clinical and psychological
cares are likely known to significantly improve the quality of life of the patient but also those
of the family. At the prodromal stage of the disease (Mild cognitive Impairment linked to AD),
there are no sufficient evidences that treating the patient improves the patient outcome. This
lack of evidence poses in some cases an ethical problem that is to announce the diagnosis of
AD at an autonomous patient who will shift irreversibly in the coming years to the dementia
stages. However, as reported in new criteria established by the National Institute on Aging
(NIA) and the Alzheimer’s Association, core clinical criteria could be used by healthcare
providers without access to advanced imaging techniques or cerebrospinal fluid analysis.
Criteria including these last advanced tools still remain in the research field [3]. On the
contrary, the diagnosis is highly aimed to be accurate at least at the clinical stage of mild
dementia, to detect the AD pathology. Core clinical criteria seems to be enough to ensure the
AD diagnosis and the use of biomarkers (imaging or CSF biomarkers) can only increase the
certainty that the basis of the clinical dementia syndrome is the AD pathophysiological process
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in a patient presenting the core clinical diagnosis [4]. The CSF biomarker panel of AD is a
picture of the neurodegeneration, the neuronal loss, the tangle formation and Aβ-amyloid42
(Aβ42) peptide accumulation in the brain. Indeed, the core CSF biomarkers for AD diagnosis
are a decrease of Aβ42 levels and more recently a decrease of the ratio of Aβ-amyloid42 / Aβ-
amyloid40 (Aβ42/Aβ40) which reflect senile plaques pathology as well as an increase of total tau
(T-tau) and phosphorylated tau (P-tau) which reflect axonal degeneration [5,6]. The use of AD
biomarker tests for routine diagnostic purposes at the present time, is only proposed as
optional for use in patients with dementia when deemed appropriate by the clinician. From
the several reasons for this limitation, the workgroup with the task of revising the 1984 criteria
for Alzheimer’s disease (AD) dementia, highlighted the limited standardization of biomarkers
from one locale to another [4]. Despite a decrease in the number of side effects associated with
the puncture, lumbar puncture remains an invasive procedure that is clearly the main factor
preventing the wide dissemination of these biomarkers in the routine. However, we cannot
ignore that the significant variability in measured biomarkers levels found in various studies,
resulting in a high variability of both the diagnostic accuracy [7] and of the clinical cut-off for
the diagnostic of AD [8], is a hindrance to the spread of these markers and their integration in
the diagnostic criteria [3]. The cut-offs obtained in Europe for CSF total tau and beta-amyloid
measured by the ELISA assays from the same manufacturer, were reported highly diverse,
with two to three fold differences between the highest and lowest reported values [8]. Three
major explanations are proposed in this report: first, the inter-laboratory comparisons are very
difficult, as some laboratories have adopted the cut-off values from the research literature
whereas others have established their own controls, these last controls being likely different
in neuropsychology evaluation, neuroimaging and the follow-up. Secondly, the lack of
standardized material between the different assays but also the lack of standardized protocols,
seem to be a major source of this variation. Finally, pre-analytical factors are those factors that
contribute to the variation of the laboratory results before the analysis of the sample. One
consensus report has already established the main pre-analytical factors that should be
standardized for CSF AD biomarkers analysis [9]. However, the importance of some pre-
analytical confounding factors highlighted in this report remained to be elucidated. The aim
of this report is to discuss and focus on main critical points in the different preanalytical steps
likely to be responsible of data variability. For analytical steps, the introduction since 2009 of
an external quality control at a large scale gave an overview of the «desaster», in the same line
that prior results. We will discuss rapidly the prior results reported in 2011 and we will
underline the urgent need for standardization.
2. Influence of confounding factors in pre-analytical phases on the analysis
of AD biomarkers
The confounding factors in pre-analytical phases have a great importance to biochemical
analysis and can affect the reliability of the results. Specially in the context of biomarkers of
AD in CSF, there are some experimental studies that support this proposition [10,11,12]. Those
factors are classically dichotomized in two different groups, «in vivo» and «in vitro». The «in
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vivo» factors are those biological factors that are linked directly to the patient, the «in vitro»
factors are linked to the procedure of sample handling and processing.
2.1. In vivo factors
2.1.1. Is there a specific time of day needed to collect the CSF?
Answering this issue needs to know if a nycthemeral cycle exists that could modify the
concentrations levels of AD CSF biomarkers during the day. Although a lack of standardiza‐
tion in the diagnostic strategy of the patient still exists, in most cases, after a first examination
including a clinical and a neuropsychological evaluation, if needed, the lumbar puncture is
generally scheduled in a second visit with morphological brain imaging in the same time, with
the aim to minimize the duration of the hospitalization. As the time of the lumbar puncture is
highly dependent of the coordinated organization of the clinical memory centre, of the
biological laboratory and of the imaging department associated with it (waiting homeostasis
results, scheduling imaging...), this question is highly relevant.
Previous results have suggested the existence of a large diurnal variability in Aβ levels during
a time period of 36 hours, but without significant differences between the hours all along the
day period [13]. Following these amazing and unexplained data, recent studies were unable
to demonstrate the existence of a temporal fluctuation in CSF biomarker levels, not only for
Aβ, but also for T-tau and P-tau [10, 14, 15]. Therefore, there is no need to standardize a specific
time interval during the day for CSF collection dedicated to the AD biomarkers assays.
2.1.2. Is fasting able to modify the concentrations levels of AD biomarkers ?
At our knowledge, there are no study that has analyzed the influence of fasting on AD CSF
biomarkers. The comparison of patients with and without fasting would give a set of indirect
and biased data without clear conclusion. Moreover, for ethical reasons, it seems to be
impossible to start a research study focused on this topic, as this study would imply a protocol
with the realization of successive lumbar punctures in a short delay. Therefore, it is not possible
to answer scientifically this issue. Nevertheless, it has been shown that, independently of the
patient food intake, Aβ levels in plasma are very stable [10]. As there is a lack of data concerning
this topic, as those kind of data could probably never be obtained, and taking account of the
large diversity in the locale organization, it is not logical to recommend fasting for the analysis
of AD biomarkers in CSF.
2.2. In vitro factors
2.2.1. Localization of the puncture
Due to the possible decreased rostro-caudal concentration gradient, the site of CSF withdrawal
must be also standardized. At our knowledge, there is no study reporting any difference
between AD biomarkers concentrations obtained by a ventricular puncture and those obtained
by lumbar puncture. Therefore, it is not recommended to analyse these markers in the
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ventricular punctures obtained during neurosurgical interventions. Nowadays, diagnostic
CSF is usually obtained by LP between the L3/L4 and L4/L5 intervertebral space.
2.2.2. Does a CSF gradient of AD biomarkers exist ?
Most brain-derived proteins have a decreased rostro-caudal concentration gradient [16].
Therefore, the volume of CSF taken can influence protein concentration. Using unpublished
data from Le Bastard et al., Vanderstichele et al reported the absence of a gradient effect in AD
CSF biomarkers concentrations during [9]. It was confirmed by another experimental study
analyzing the gradient effect in the spinal cord on Aβ42 [10]. Therefore, there is no reason to
recommend any specific fraction of CSF volume for the assay of AD biomarkers.
2.2.3. What kind of needle for the puncture ?
The type of needle is likely known to influence the percentage of side effects in patients and
to be a factor leading to the presence of red cells [17, 18]. Therefore, the needle could influence
the biomarkers concentrations. It has been shown that post-lumbar puncture headache (PLPH)
severity was significantly decreased when a 22G needle was used instead of a 20G needle [18].
Moreover, using a 22G atraumatic needle it was also observed a remarkably decrease of PLPH
in comparison with 22G traumatic needles [19]. Finally, as lumbar puncture is sometimes
difficult with 25G needle in elderly people, a korean group has compared the prevalence of
PLPH using 23G and 25G needles. They concluded that the choice of a 23 or 25 gauge Quincke
needle has no significant influence on post-dural puncture headache for Korean patients
greater than 60 years old. Therefore, the 23 gauge Quincke needle is an option for lumbar
punctures in this patient population [20].
2.2.4. Types of sampling tubes
It was established that polypropylene (PP) tubes should be preferred to glass or polystyrene
tubes for collection of the CSF since Aβ peptides, but also T-tau and P-tau, bind in a non
specifically manner to the polystyrene tubes and to the glass tubes [10, 21]. However, two
independent studies reported significant differences on Aβ42 levels (up to 50 % compared to
basal values !) when CSF was collected in PP tubes from different suppliers [11, 22]. For Aβ42,
we found that adsorption was effective in a contact time less than 15 minutes, the loss of Aβ42
levels being highly significant [11]. Moreover the adsorption intensity was highly dependent
on the levels of total proteinorachia, since we abolished this phenomenon when we spiked the
CSF with solutions of bovine serum albumin. Amazingly, we also shown that, whereas all the
tubes that we studied were commercialized by the providers as tubes in PP, a calorimetry and
a spectroscopy analysis revealed that just one out of 11 tubes was pure PP while the others
were copolymers made of PP and polyethylene (PE) [11]. Moreover, we also shown that the
pure PP causes more adsorption of amyloid peptides than tubes in copolymers of PE and PP,
with or without treatment surface, and that some tubes in copolymers could be worst than
classical polystyrene: these highly striking results were reproducible in the independent
laboratories which have collaborated in this study [11]. Moreover, it was also observed that
the tubes that performed better for Aβ42 were the worst for P-tau suggesting that hydrophilic-
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hydrophobic balance is a important point in protein adsorption [11, 23]. The variability of
adsorption intensity of proteins onto the plastic of the tube is the result of the incredible jungle
of the manufacturing of different tubes called PP: difference in the nature and in the percentage
of the copolymers in the plastic, presence of additives, surface treatments, modification of the
surface by the sterilization process... The possibility of modifying the protein adsorption by
additives or surface treatments was underlined by different reports. First, when Tween-20 was
added in the tube containing the CSF, the adsorption of amyloid peptides was significantly
reduced [22]. Secondly we recently reported similar results using various plasma treatments
of the tube surface, able to modify the adsorption of different proteins like prion protein, Tau
and alpha synuclein [23]. These data highlight the need to standardize also the type of test tube
used since the great variability found could even lead to a possible AD misdiagnosis. In our
laboratory, we shifted to the best tube that we found in this study. This shift has introduced
an averaged increase of 25 % of Aβ42 levels leading to a modification of our cut off diagnostic
value from 500 ng/L to 700 ng/L (data submitted). Currently the members of the Joint Pro‐
gramming Neurodegenerative Disease research (JPND) are performing a study which includes
the analysis of the most suitable type of tube for AD CSF biomarkers research. Therefore, it is
not reasonable to follow the actual guidelines recommending the use of generic PP tubes. Since
the data of the JPND collaboration will probably not be available before 2 or 3 years, the best
compromise would be that each laboratory concerned by these markers, compares its local
tube with the best tubes identified in our study, which are easily available in the commercial
market.
2.2.5. Time delay between CSF collection and storage before assay
This is an issue difficult to standardize due the high variety of existing procedures and its
probable  dependance of  confounding factors  (hemorragic  puncture,  hemolyzed samples,
high levels of total protein, one sampling tube for AD biomarkers and various markers of
others pathologies...) which could modify the stability of the biomarkers during this critical
period.
For that, we will discuss first the need to centrifuge and the protocol of centrifugation. This
step is able to avoid the presumed influence of the blood cells introduced by the hemorragic
puncture. These hemorragic punctures occur in 14-20% cases of lumbar puncture. Bjerke et al.
were unable to detect any difference in Aβ42 levels when up to 5000 erythrocytes/µl were spiked
to the CSF. This value was found ten fold higher than those recommended in the regulation’s
document included in the Innogenetics kits. However, they found significant decreased Aβ42
levels in CSF when plasma was added which was attributed to the binding of Aβ42 to different
plasma proteins [10]. We cannot also neglect the presence of plasmatic proteases able to digest
the peptides since it has been shown that blood contamination of CSF can also lead to protein
degradation [25]. The guidelines of Vanderstichele et al. pointed out the absence of difference
on the levels of Aβ42, T-tau and P-tau between centrifuged and non-centrifuged samples (N.
Le Bastard, unpublished data) [9] which could be explained by the fact that they used clear
CSF samples. In these guidelines, it was pointed out that spinning speed did not modify
significantly the concentration levels of the biomarkers. More recently, it was reported that the
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sample temperature was always similar to the temperature set up in the centrifuge showing
that temperature is not increased by spinning itself [26]. We can then recommend, that
centrifugation should be performed at 2,000 g during 10 minutes at room temperature (RT)
following the standardized protocol [26].
If several publications and recommendations are related to the delay between sampling and
storage [27], it seems that there is a lack of conclusive data about the influence of the delay
between sampling and centrifugation for AD biomarkers, mainly for hemorragic puncture.
Nevertheless, it was reported significant changes of various metabolites, various amino acids
and proteins in presence of white blood cells in the CSF, using a proteomics approach when
the CSF were left at RT in the first 30 minutes [28].These data could explain the apparent
discrepancy between the study of Kaiser et al, describing a significant increase of the levels of
Aβ42 after 24 hours [29] and those of Bjerke, describing that Aβ42 concentrations remained stable
up to 24 hours after the sampling (storage at RT) [10]. The lack of centrifugation prior incuba‐
tion is likely the reason of the increase in Aβ42 previously observed. Taken all together, all these
data highlight the importance of centrifugation to be realized, as soon as possible after
sampling, for CSF biomarker analysis.
Although the aspect of the CSF was not always indicated, we can imagine that the different
studies which have reported a stability of the CSF levels of Aβ42, Aβ40, T-tau and P-tau over a
period of 24 h at least, were done with clear CSF. Thus, the concentrations of Aβ42 were found
stable 24 h [10], 72 h when the sample was stored at 4°C [12] and up to 7 days after LP at RT
[30]. It was the same for the concentrations of T-tau [10, 12, 29, 30]. Regarding the temperature
during the time delay, no significant difference was found between the storage of the CSF
samples at RT, 4°C or frozen in any of the studies performed [9, 10].
2.2.6. Freezing process
This process is complex since different factors could influence the biomarkers concentra‐
tions: although it seems clear that heterogeneity also exists for storage tubes, the tempera‐
ture of freezing, the volume of the aliquots, the length of the storage and the possible effect
of freezing / thawing cycles are potential factors to evaluate. Moreover, these factors can
be synergistic:  the adsorption of  proteins onto the tube walls  could be increased by the
lower volume of the aliquot and mainly by the ratio volume / surface, or by the tempera‐
ture of freezing (-20 versus -80°C).
The first step is to choose a storage tube. In parallel to the test realized with 11 sampling tubes
[11], we selected 9 different commercially available polypropylene storage tubes (Table 1, tubes
13 to 21), some of them being used by different clinical teams in the AD field. The volume
capacity was ranged from 0,5 to 1,5 mL. We performed an analysis of the surface polymer
composition using differential scanning calorimetry and Fourier Transformed Infrared
spectroscopy. This revealed the same surprising results than obtained with the sampling tubes
[11]: only one tube was constituted by pure polypropylene, the others being copolymers with
at least polyethylene, with or without surface treatment. Using the same protocol as described
for the sampling tubes [11], biomarkers concentrations showed variations that were signifi‐
cantly different for Aβ42 peptide. Median values for Aβ42 peptide varied from 94 % to 127 %.
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These data confirmed those obtained for sampling tubes, although the variability was lower
than those found with these last tubes. The effect was present after 15 min, but increasing the
incubation time to 24h at 2-8°C, the values did not significantly change compared to 15 minutes
incubation.
The next step consists to standardize if needed the temperature, i.e. the speed, of freezing.
Freezing temperatures may affect CSF proteins concentrations as it has previously been
reported for cystatin C, which undergoes a proteolysis at -20°C but not at -80°C [31]. Recently,
the levels of T-tau and P-tau were reported significantly lower when CSF samples were
immediately frozen at -20°C instead of -80°C (N. Le Bastard, unpublished data) [19]. However,
this group did not find any difference for the Aβ42 levels when the CSF were frozen at -20°C
or -80°C, confirming previous results [10]. Therefore, freezing and storage at -80°C the CSF
samples, seem to be logical.
Aliquoting the supernatant of CSF is absolutely necessary since it avoids different Freeze/thaw
cycles (see below). Although we did not realize a study designed to evaluate the possible
synergy between the ratio volume/surface and the speed of freezing onto the absorption
phenomenon in these storage tubes (total volume less than 1.5 ml), some procedures issued
from previous reported guidelines can be logically applied [27]. They pointed out the need to
use small volumes (never more than 0.5 ml), which would allow: a/to realize at least the assay
of the 3 classical AD biomarkers and if needed the assay of Aβ40, b/ to prevent freeze/thaw
cycles and c/ fill the tube up to 75% to minimize the adsorption and the evaporation effect, this
last effect being negligible when the sample is stored frozen at -80°C [26].
As mentioned before, the guidelines recommend separating the supernatant in several
fractions, that which will reduce the numbers of freeze/thaw cycles since freezing was shown
able to affect protein stability [32]. Some studies have already analyzed the influence of freeze/
thaw cycles on AD CSF biomarkers. Most studies using an ELISA format no have found any
change on Aβ42 and Tau CSF levels after one freeze/thaw cycle [10, 12, 30, 33], whereas a
significant loss of Aβ42 was found after one single cycle in one study using a semi-quantitative
method [34]. Increasing the number of cycles was reported able to modify the stability of Aβ42
CSF levels. However, about the exact numbers of cycles able to impact the levels, no real
consensus was found between the different studies. If the Tau CSF levels seem to be unaffected
by 3 or 6 freeze/thaw cycles [30, 12], the Aβ42 CSF levels were found either stable after 3 cycles
[30], either were significantly decreased after the third cycle [12]. In case of immunoassay
analysis, it is logically recommended to limit the number of freeze/thaw cycles up to two as
maximum [9].
Finally,  the  length  of  storage  at  -80°C  does  not  seem  to  present  a  major  influence  on
stability  of  CSF AD biomarkers,  at  least  for  2  years  [30]  according to  unpublished data
from Blennow K. et al., referenced in the guideline published by Vanderstichele et al. [19].
Moreover, the levels of Aβ42 and T-tau but not Aβ40, remained stable up to 6 years [35]. In
summary, we can conclude that CSF can be stored up to 2 years at -80°C as previously
reported [19].
Pre-Analytical and Analytical Critical Factors Influencing the High Variability of the Concentrations Levels of...
http://dx.doi.org/10.5772/55512
183
3. Variability introduced by the analytical step
There are several available assays for the determination of CSF Aβ42, T-Tau and P-Tau,
commercialized by different companies (Covance, Cusabio, IBL international, Innogenetics,
Invitrogen, Millipore, Meso Scale Discovery, Wako... list not exhaustive). Large variation, in
assay performance and outcomes of CSF Aβ42, T-Tau and P-Tau levels was observed between
laboratories also when the same assay format was used, reaching in some cases an inter-assay
and inter-laboratory coefficient variations of 20 to 35% [7, 36]. As shown in conclusions of the
first report of the external quality control (EQC) program started by the Alzheimer’s associa‐
tion [37], ELISA techniques dominate the market while multiplex techniques are used less. In
this program, for Aβ42, T-Tau and P-Tau, most of laboratories [26 laboratories) used the
INNOTEST enzyme-linked immunosorbent assays (ELISAs) (Innogenetics, Ghent, Belgium,
www.innogenetics.com), whereas 14 laboratories used the bead-based Luminex xMAP
platform with the INNO-BIA AlzBio3 (Innogenetics, Ghent, Belgium, www.innogenet‐
ics.com). Moreover, for Aβ42 and T-Tau, 5 laboratories used Meso Scale Discovery (MSD,
Gaithersburg, MD, www.mesoscale.com) technology [37].
3.1. Principles of assays
INNOTEST enzyme-linked immunosorbent assays (ELISAs) (Innogenetics) are classical
ELISAs with colorimetric detection.
INNO-BIA AlzBio3 allows the simultaneous quantification of Aβ42, T-Tau and P-Tau in CSF
using xMAP® technology (xMAP is a registered trademark of Luminex Corp). The micro‐
sphere-based Luminex xMAP technology involves covalent coupling of a capture antibody to
spectrally specific fluorescent microspheres [38]. Each microsphere number has a unique
spectral identity. The classification of each bead is made by excitation at 635 nm. Each bead
number is linked with only one antibody and the signals from analytes in the mixture are
identified unequivocally. The quantification of the molecular reaction that has occurred at the
microsphere surface, is done using a fluorochrome, the phycoerythrin coupled to streptavidin.
The intensity of the fluorescence, derived after excitation of PE at 532 nm, is reported.
MSD offers the possibility to measure in simplex or multiplex format, depending on the
biomarker analysed. Whereas t-Tau is measured in simplex format by the participants of
the  external  control  program,  Aβ42  can  be  measured  in  simplex  or  multiplex  format  in
combination with Aβ38 and Aβ40. Multi-array plate formats include 96- and 384-well plates.
The multi-spot plates are available with up to 100 spots per well. MSD uses electrochemi‐
luminescence  to  detect  binding  events  on  patterned  arrays.  Electrochemiluminescence
detection  uses  labels  that  emit  light  at  ~620  nm when electrochemically  stimulated,  the
stimulation mechanism (electricity) being decoupled from the signal (light). The signals are
treated by the SECTOR Imager Instrument, which is medium throughput imaging detection
systems (charge-coupled device camera), capable of multiplexing in all  spot formats and
reads 96- and 384-well plates.
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3.2. Extent of the variability highlighted by this EQC program [37]
3.2.1. Total variability
In this report, results were grouped according to analytical techniques and samples [37].
The total CVs among centers were 16% to 28% for ELISA, 13% to 36% for xMAP, and 16%
to 36% for MSD. CVs for MSD must be interpreted with caution, because they included 2
different Monoclonal antibodies (Mab) for Aβ42 assays, binding to different epitopes on the
amyloid peptide. These data were totally conformed to those reported earlier [7, 36]. There
was no major modification of the CV in the longitudinal evaluation, except a decrease in
variation  for  T-tau  measured  by  ELISA.  This  was  expected,  since  there  was  no  active
intervention between the 2 rounds [37].
3.2.2. Within-laboratory precision
Within-laboratory CVs were examined at the reference laboratories for ELISA and xMAP
in two consecutive rounds. CVs were 3.2% to 24% for ELISA and 2.3% to 26% for xMAP,
but differed between analytes within individual laboratories,  indicating assay-dependent
variations [37].
3.2.3. Differences in absolute values
The analytical techniques reported different absolute values for the biomarkers. ELISA values
for Aβ42, were about 2 fold higher than xMAP values. MSD values for Aβ42, were dependent
of the Mab used. ELISA values for T-Tau were about 3 fold higher than xMAP values. Finally
for P-Tau, the differences inter techniques were clearly decreased in comparison to Aβ42, and
T-Tau. Considerable variability exists among the same manufacturer between mono and
multiplex technology. For example, the decision threshold of clinical disease was reported to
be at 86 pg / mL and 350 pg / mL for T-TAU measured by xMAP technology of Innogenetics
on the platform Luminex and the conventional ELISA, respectively [39]. Factors of correction
between values obtained by xMAP and ELISA, were used for global comparison of groups of
patients, i.e. controls, Mild Cognitive Impairment and AD patients to predict incipient AD by
CSF biomarkers [40]. In an other side, it was clearly shown that the use of factors of correction
did not resolve the discrepancy in values observed between xMAP and ELISAs [41]. Although
the observed biomarker concentrations may vary significantly between platforms, including
MSD, xMAP and ELISA, these techniques seem to have similar diagnostic accuracy for patients
with AD versus controls [39] or for detecting early AD [41, 42].
3.3. Possible sources of variability
In this study analysing the variability of results from only two rounds of an EQC program and
from many different assay lots used, the authors limited their interpretation of the relative
contributions from between-laboratory, within-laboratory, and between-lot components to the
total variability [37]. Differences in within-laboratory CVs among the biomarkers within
individual reference laboratories suggest that assay-related factors are important. Moreover,
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the high variability of the results of biomarkers measured by different commercial kits can be
explained, by the use of different antibodies, the nature of the calibrator, the calibration method
and many others factors as for example the nature of standard. Increasing data during years
and by incorporation of new centers (since this first report concerning 40 laboratories, in
summer of 2012, 64 laboratories were participating at this program) will permit to better
identify the major sources of variability in analytical steps. Thus, we can just list the different
points to be further investigated.
In the laboratory, the biologist will take care for:
a. Pipetting
The pipetting mode (inverse pipetting...) is not specified by the manufacturer. Using a single
tip can influence the standard curve accuracy. However, the magnitude of this effect, if any,
should be tested, to provide a better basis for recommendation [43].
b. Calibration
For lyophilised standard, accurate solubilization and accurate pipetting is critical. Moreover,
since for INNOTEST Ab42, the first point of the curve calibration must be adjusted depending
of the set value, accurate pipeting is absolutely needed. The type of curve fitting used and the
software for data calculation were shown as possible factors of variability [43].
c. Reagent handling and adhesion of biologists to the manufacturer standard operating
procedure (SOP)
The adhesion of routine laboratories to the manufacturer SOP is absolutely needed to reduce
the part of the variability found in CSF biomarkers analysis. For that, a great effort must be
done by the different manufacturers to limit individual interpretation of the technical instruc‐
tions. The best example consists in the definition of the «room temperature» which can mainly
vary from the north to the south of Europe. The maintenance of laboratory equipment is a
crucial point to ensure the accuracy of pipeting volumes, the accuracy of temperatures, the
accuracy of detection signals and the quality and reproducibility of washing steps.
d. Familiarization with the method and Competency Train
Implementing these techniques in the laboratory needs a training program ensured by the
manufacturer. Moreover, habilitation and qualification of the laboratory staff must be done.
e. Validation criteria of runs for rejecting data
Different means are used to ensure validation of results. The definition of the criteria of
acceptance of results must be strict. They include the calibration curve parameters, the CV of
the duplicate samples and the use of an internal quality control program. For the CV criteria
acceptance, in our experience, it seems that they are to be adequately defined since, the
recommendation of CV < 20% done in the INNOTEST documentation, is not acceptable all
along the dynamical range of the assay, in particular when the concentration level is near the
clinical cut-off. Moreover, in the absence of QC samples in the kit, the biologist needs to
implement its own QC program with different crucial points to resolve: the nature of the
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sample (native CSF pools, spiked CSF with standards, peptides...) how many QC samples,
range of concentrations to cover, absence of reference material. This point is crucial for
laboratories concerned by accreditation scheme based on the application of ISO15189 standard.
3.3.1. Issues to be solved by manufacturers
Many crucial points need to be solved as the poor quality of the test procedure instructions to
decrease variability induced by misunderstanding of the protocols. This lacking information
is often an indicator of minimal method optimization of the protocol (for example incubation
steps, handling the reagents...). The reagents must be proposed in a manner that permits to
decrease variability, for instance the «ready to use» calibrators. The absence of quality control
included in the kit is a major problem. In fact, part of the discrepancy observed in the concen‐
trations levels between the analytical techniques ELISA, xMAP, and MSD is caused by the lack
of certified reference materials (CRMs). This could mainly impact the interlot variability and
is at least, a brake to standardization. Antibody purification, coating of plates and beads are
also factors of lot-lot variability.
4. Conclusion
The present chapter highlights two main issues responsible for the lack of harmonization of
CSF AD biomarkers cut-offs values: the lack of standardization of the pre-analytical steps and
the high variability of results linked to the analytical step. This latter issue can be explained
by the absence of transferability of results between the different platforms but also by the high
inter laboratory dispersion within the same assays. Previous consensus guidelines for pre-
analytical factor standardization gave the way to resolve this issue, evidencing the need to
standardize sampling and storage tubes, the type of the needle for the CSF puncture and the
long term storage. Establishing SOPs for sample processing would allow to compare diagnostic
conclusions between different laboratories. The implementation of those SOPs in the clinical
community may reduce part of the variability found in the analysis of AD CSF biomarkers.
Antibody purification, coating surfaces, preparation of standards, manufacturers instructions
are also sources of variation, which need to be decreased and requires increased efforts by kit
manufacturers. The optimal approach is a collaborative effort between commercial kit and
instrument platform manufacturers, laboratories concerned by those methods, and reference
standardization programs.
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